PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 3, 2000, Pages 459-463

  Gracey, David J ^a   Bell, Robert ^a   King, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

CCK; Latent inhibition; PD 135,158; Rat model of psychosis

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; HALOPERIDOL; PD 135158;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRINKING; DRUG ACTIVITY; LATENT INHIBITION; LICKING; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0033984459     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00227-0     Document Type: Article

References (49)

1. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Mental Dis. 176:1988;598-606.
2. Britton D.R., Yahiro L., Cullen M.J., Kerwin J.F., Kopecka H., Nadzan A.M. Centrally administered CCK suppresses activity in mice by a peripheral-type CCK receptor. Pharmacol. Biochem. Behav. 34:1989;779-783.
3. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons. Effects of antipsychotic drugs and amphetamine on single cell activity J. Pharmacol. Exp. Ther. 185:1973;560-571.
4. Christison G.W., Atwater G.E., Dunn L.A., Kilts C.D. Haloperidol enhancement of latent inhibition. Relation to therapeutic action? Biol. Psychiatry. 23:1988;746-749.
5. Cohen S.L., Knight M., Tamminga C.A., Chase T.N.A. Cholecystokinin-octapeptide effects on conditoned-avoidance behavior, stereotypy and catalepsy. Eur. J. Pharmacol. 83:1982;213-222.
6. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
7. Crawley J.N., Fiske S.M., Evers J.R., Austin M.C., Beinfeld M.C. Functional analyses of the coexistence of CCK and dopamine. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. Multiple CCK receptors in the CNS. 1992;368-384 Oxford University Press, Oxford, UK.
8. Dunn L.A., Atwater G.E., Kilts C.D. Effects of antipsychotic drugs on latent inhibition. Sensitivity and specficity of an animal model of clinical drug action Psychopharmacology (Berlin). 112:1993;315-323.
9. Ellenbroek B.A., Cools A.R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1:1990;469-490.
10. Feifel D., Swerdlow N.R. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci. Lett. 229:1997;5-8.
11. Feldon J., Weiner I. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol. Psychiatry. 29:1991;635-646.
12. Gracey D.J., Bell R., King D.J., Trimble K.M., McDermott B.J. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide. Pharmacol. Biochem. Behav. 4:1998;1053-1059.
13. Gray A.S., Pickering A.D., Hemsley D.R., Dawling S., Gray J.A. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berlin). 107:1992;425-430.
14. Gray N.S., Hemsley D.R., Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiat. Brain Res. 1:1992;83-89.
15. Hill D.R., Singh L., Boden P., Pinnock R., Woodruff G.N., Hughes J. Detection of CCK receptor subtypes in mammalian brain using highly selective non-peptide antagonists. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. Multiple CCK receptors in the CNS. 1992;57-76 Oxford University Press, Oxford, UK.
16. Hökfelt T., Rehfeld J.F., Skorboll L., Ivemark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature. 285:1980;476-477.
17. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Development of a class of selective CCK type B receptor antagonists having potent anxiolytic activity. Proc. the Nat. Acad. Sci. 87:1990;6728-6732.
18. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia. A review Schizophr. Bull. 2:1976;19-76.
19. Meltzer L.T., Christoffersen C.L., Serpa K.A., Razmpour A. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area. Synapse. 13:1993;117-122.
20. Montgomery S.A., Green M.C.D. The use of cholecystokinin in schizophrenia. A review Psychol. Med. 18:1988;593-603.
21. Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann. NY Acad. Sci. 713:1994;300-311.
22. Rasmussen K., Stockton M.E., Czachura J.F., Howbert J.J. Cholecystokinin (CCK) and schizophrenia. The selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity Eur. J. Pharmacol. 209:1991;135-138.
23. Rasmussen K., Czachura J.F., Stockton M.E., Howbert J.J. Electrophysiological effects of diphenylpyrazolidinone CCK-B and CCK-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 264:1993;480-488.
24. Rasmussen K., Stockton M.E., Czachura J.F., Howbert J.J. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691. Mediation through feedback pathways from forebrain sites Synapse. 15:1993;95-103.
25. Rasmussen K., Yu M.J., Czachura J.F. Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity. Synapse. 17:1994;278-282.
26. Rasmussen K., Gates M.R., Burger J.E., Czachura J.F. The novel atypical olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neurosci. Let. 222:1997;61-64.
27. Rupniak N.M.J. CCK-dopamine interactions. Implications for treatment of schizophrenia Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. Multiple CCK receptors in the CNS. 1992;385-394 Oxford University Press, Oxford, UK.
28. Schneider L.H., Alpert J.E., Iversen S.D. CCK-8 modulation of mesolimbic dopamine. Antagonism of amphetamine-stimulated behaviors Peptides. 4:1983;749-753.
29. Skirboll L.R., Grace A.A., Hommer D.W., Rehfeld J., Goldstein M., Hokfelt T., Bunney B.S. Peptide monamine coexistence. Studies of action of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons Neuroscience. 6:1981;2111-2124.
30. Solomon P.R., Staton D.M. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore irrelevant stimulus. Biol. Psychiatry. 17:1982;743-756.
31. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry. 51:1994;139-154.
32. Swerdlow N.R., Braff D.L., Hartson H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
33. Thornton J.C., Dawe S., Lee C., Capstick C., Corr P.J., Cotter P., Frangou S., Gray N.S., Russell M.A.H., Gray J.A. Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berlin). 127:1996;164-173.
34. Trimble K.M., Bell R., King D.J. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol. Biochem. Behav. 56:1997;809-816.
35. Trimble K.M., Bell R., King D.J. Enhancement of latent inhibition in the rat at a high dose of clozapine. J. Psychopharmacol. 12:1998;215-219.
36. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity. Evidence for rostral-caudal differences in accumbens CCK function Behav. Neurosci. 103:1989;821-826.
37. Van Megen H.J.G.M., Westenberg H.G.M., Den Boer J.A., Kahn R.S. Cholecystokinin and anxiety. Eur. Neuropsycho-pharmacol. 6:1996;263-280.
38. Van Ree J.M. Neuropeptides and psychopathology. J. Controlled Rel. 29:1994;307-315.
39. Van Ree J.M., Gaffori O., De Weid D. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur. J. Pharmacol. 93:1983;63-78.
40. Weiner I. Neural substrates of latent inhibition. The switching model Psychol. Bull. 108:1990;442-461.
41. Weiner I., Feldon J. Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology (Berlin). 91:1987;248-253.
42. Weiner I., Lubow R.E., Feldon J. Chronic amphetamine and latent inhibition. Behav. Brain Res. 2:1981;285-286.
43. Weiner I., Lubow R.E., Feldon J. Disruption of latent inhibition acute administration of low doses of amphetamine. Pharmcol. Biochem. Behav. 30:1988;871-878.
44. Weiner I., Smith A.D., Rawlins J.N.P., Feldon J. A neuroleptic-like effect of ceronapril on latent inhibition. Neuroscience. 49:1992;307-315.
45. Weiner I., Tarrasch R., Hasson O., Forian R., Smith A.D., Rawlins J.N.P., Feldon J. The effects of chronic administration of ceronapril on the partial reinforcement extinction effect and latent inhibition in rats. Behav. Pharmacol. 5:1994;306-314.
46. Weiner I., Shadach E., Barkai R., Feldon J. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning. Implication for the mechanism of action of neuroleptic drugs Neuropsychopharmacology. 16:1997;42-50.
47. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., Rawlins J.N.P. Antipsychotic drug effects in a model of schizophrenic attentional disorder. A randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people Biol. Psychiatry. 40:1996;1135-1143.
48. Williams J.H., Wellman N.A., Geaney D.P., Feldon J., Cowen P.J., Rawlins J.N.P. Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology (Berlin). 133:1997;262-268.
49. Xu X.J., Puke M.J.C., Verge V.M.K., Wiesenfeld-Hallin Z., Hughes J., Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosc. Lett. 152:1993;129-132.